anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Female participants over the age of 15 randomized to the intervention group will participate in working group sessions over 12 weeks' time that addresses plastic waste and introduce strategies to reduce use, recycle, and repurpose plastic. Community members of participants in the intervention group will also be invited to participate in the working groups.
The purpose is to produce a cosmetic efficiently and stably which comprises a complex of a fullerene and Ϝ-cyclodextrin and which can reduce the amount of active oxygen generated by irradiation of a living body with UV ray. A fullerene and Ϝ-cyclodextrin in an amount which is not less than three times the mass of the fullerene and is less than 8 times the mass of the fullerene are charged in a mortar and then milled and mixed together in the mortar. A solvent is added to the resulting solid mixture. The mixed solution is applied with ultrasonic vibration. The resulting mixed solution is filtered. The filtrate is a solution of a complex of the fullerene and Ϝ-cyclodextrin. This solution shows no cytotoxicity even at a higher concentration and can scavenge active oxygen. Thus, a complex of a fullerene and Ϝ-cyclodextrin or a solution of the complex is useful as a cosmetic.
BACKGROUND: Frequent natural disasters like floods pose a major threat to India, with significant implications for public health. Low birth weight (LBW) is a critical global health concern, contributing to neonatal mortality. However, the association between floods and LBW remains underexplored. This study aims to address this gap by investigating the association between flood hazards and LBW in India using a geospatial approach. By analyzing data from the National Family Health Survey (NFHS-5) and flood zonation maps, the study aims to uncover the spatial dynamics of this association, offering insights into the implications of floods on birth weight across diverse geographical regions.
METHODS: The study used the fifth round of NFHS data, 2019-21, which involved 202,194 children selected through a multi-stage stratified sampling technique. The Vulnerability Atlas of India 2019 maps were also utilized to classify areas as flood or non-flood zones. Birth weight data from the NFHS-5 were categorized into three groups: very low, low, and normal birth weight (VLBW, LBW and NBW). Control variables including flood exposure, socio-demographic attributes, and geographic region were considered. Bivariate analysis and multinomial logistic regression were employed for statistical analysis. The spatial analysis involved Moran's I statistics and Geographically Weighted Regression to explore spatial dynamics of the association between floods and birth weight in India.
RESULTS: Floods predominantly affect India's lower Himalayan belts and western coastal regions. Flood-affected areas show higher proportions of VLBW and LBW infants. Groundwater usage and unimproved sanitation are associated with higher risk of VLBW and LBW. Sex, wealth, maternal education, residence type, and geographic region significantly influence birth weights. Multinomial logistic regression reveals 8 % and 27 % higher risks for LBW and VLBW in flood-affected regions. LISA cluster maps identify high-risk areas for both LBW and floods. Geographically Weighted Regression highlights 52 % of the variability in LBW occurrences can be attributed to the influence of flood hazards. Families hailing from the poorest wealth background and exposed to flood hazards bear a 5 % heightened likelihood of delivering LBW infants, in stark contrast to their counterparts from the same economic background yet unaffected by floods.
CONCLUSIONS: The significant association between floods and LBW underscores the importance of robust disaster preparedness and public health strategies. By unraveling the spatial intricacies of flood-induced LBW disparities, this research provides valuable insights for promoting healthier birth outcomes and reducing child mortality rates, particularly in flood-prone regions. These findings emphasize the importance of holistic policies that address both environmental challenges and socioeconomic inequalities to safeguard maternal and infant health across the nation.
Both the 1 mL vial and the 1 mL prefilled syringe of Medroxyprogesterone Acetate Injectable Suspension, USP should be vigorously shaken just before use to ensure that the dose being administered represents a uniform suspension.

The recommended dose is 150 mg of Medroxyprogesterone Acetate Injectable Suspension, USP every 3 months (13 weeks) administered by deep IM injection in the gluteal or deltoid muscle. Medroxyprogesterone Acetate Injectable Suspension, USP should not be used as a long-term birth control method (i.e. longer than 2 years) unless other birth control methods are considered inadequate. Dosage does not need to be adjusted for body weight [See Clinical Studies (14.1)].

To ensure the patient is not pregnant at the time of the first injection, the first injection should be given ONLY during the first 5 days of a normal menstrual period; ONLY within the first 5-days postpartum if not breast-feeding; and if exclusively breast-feeding, ONLY at the sixth postpartum week. If the time interval between injections is greater than 13 weeks, the physician should determine that the patient is not pregnant before administering the drug. The efficacy of Medroxyprogesterone Acetate Injectable Suspension, USP depends on adherence to the dosage schedule of administration.
Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
The dosage of memantine hydrochloride extended-release capsules shown to be effective in a controlled clinical trial is 28 mg once daily. 

The recommended starting dose of memantine hydrochloride extended-release capsules is 7 mg once daily. The dose should be increased in 7 mg increments to the recommended maintenance dose of 28 mg once daily. The minimum recommended interval between dose increases is one week. The dose should only be increased if the previous dose has been well tolerated. The maximum recommended dose is 28 mg once daily.

Memantine hydrochloride extended-release capsules can be taken with or without food. Memantine hydrochloride extended-release capsules can be taken intact or may be opened, sprinkled on applesauce, and thereby swallowed. The entire contents of each memantine hydrochloride extended-release capsule should be consumed; the dose should not be divided.

Except when opened and sprinkled on applesauce, as described above, memantine hydrochloride extended-release capsules should be swallowed whole. Memantine hydrochloride extended-release capsules should not be divided, chewed, or crushed.

If a patient misses a single dose of memantine hydrochloride extended-release capsules, that patient should not double up on the next dose. The next dose should be taken as scheduled. If a patient fails to take memantine hydrochloride extended-release capsules for several days, dosing may need to be resumed at lower doses and retitrated as described above.
PIF-I and STAS were administered to the Reiki group through an online questionnaire. After the pretests of the students were completed, between 14-17 June 2022, the distant reiki application was made under the guidance of a researcher with a Usui Reiki Master \&Teacher degree and by the researchers with Reiki -II or Reiki-III degrees. The application was carried out for 20 minutes on four consecutive days. Before the final exams (19 June 2022), the posttests (PIF-II and STAS) were applied to the students through an online questionnaire.
NEW MATERIAL:A caffeic acid derivative of formula I (R1 and R2 are hydroxyl, alkoxy, respectively; n is 6-14). EXAMPLE:Caffeic acid hexylamide. USE:Since it has an action to inhibit lipoxygenase and inhibit the synthesis of leucotriene and 5-HETE in vivo in mammarians such as men, horses, dogs, guinea pigs, mice or rats, it is used as a remedy or preventive for allergic diseases, asthma and inflammation. PREPARATION:For example, the reaction of caffeic acid or its reactive derivative with a compound of formula I give the compound of formula I. In case that caffeic acid is used in the form of its free acid, it is preferred to use a dehydrating agent such as N,N'-dicyclohexylcarbodiimide. The reaction is preferably carried out in a solvent such as tetrahydrofuran or acetonitrile at room temperature to 50 deg.C.
Among candidate new diagnostics for TB, a test for mycobacterial Lipoarabinomannan (LAM) excretion in urine has shown promising results in one Tanzanian study: The sensitivity for detecting TB culture-positive patients was 80.3%. Of 103 healthy volunteers, only one gave a false positive result (Boehme, 2005).

Until now, there are only data concerning this test for diagnosis of adult disease. For evaluation of routine use in children in countries like Malawi, we are starting a prospective study. Children 0-14 years of age with suspected TB will be investigated using TB culture as the gold standard. In sputum samples, microscopy will be done. Simultaneously, LAM Elisa from the patient´s urine will be done.
The side effects of high-dose dexamethasone in anti-infection include increased ROS production and immune cell apoptosis. Dexamethasone effectively activates serum/glucocorticoid-regulated kinase 1 (SGK1), which upregulates various ion channels by activating store-operated calcium entry (SOCE), leading to Ca2+ oscillations. PIEZO1 plays a crucial role in macrophages' immune activity and function, but whether dexamethasone can regulate PIEZO1 by enhancing SOCE via SGK1 activation remains unclear. The effects of dexamethasone were assessed in a mouse model of sepsis, and primary BMDMs and the RAW264.7 were treated with overexpression plasmids, siRNAs, or specific activators or inhibitors to examine the relationships between SGK1, SOCE, and PIEZO1. The functional and phenotypic changes of mouse and macrophage models were detected. The results indicate that high-dose dexamethasone upregulated SGK1 by activating the macrophage glucocorticoid receptor, which enhanced SOCE and subsequently activated PIEZO1. Activation of PIEZO1 resulted in Ca2+ influx and cytoskeletal remodelling. The increase in intracellular Ca2+ mediated by PIEZO1 further increased the activation of SGK1 and ORAI1/STIM1, leading to intracellular Ca2+ peaks. In the context of inflammation, activation of PIEZO1 suppressed the activation of TLR4/NFκB p65 in macrophages. In RAW264.7 cells, PIEZO1 continuous activation inhibited the change in mitochondrial membrane potential, accelerated ROS accumulation, and induced autophagic damage and cell apoptosis in the late stage. CaMK2α was identified as a downstream mediator of TLR4 and PIEZO1, facilitating high-dose dexamethasone-induced macrophage immunosuppression and apoptosis. PIEZO1 is a new glucocorticoid target to regulate macrophage function and activity. This study provides a theoretical basis for the rational use of dexamethasone.
The invention discloses a cell carrier-based composition, a responsive supramolecular cell drug-loaded system, a preparation method and application thereof. The cell vector-based composition comprises a first part and a second part; the first part is a first cell with a macrocyclic host molecule embedded in the cell membrane, and the second part is a guest molecule modified nanoparticle or a second cell. Or, the cell membrane of the first cell is embedded with a guest molecule, and the second part is a macrocyclic host molecule modified nanoparticle or a second cell. The macrocyclic host molecule and the guest molecule can mutually recognize to form a host-guest complex with a responsive fracture characteristic. Due to the stimulation responsiveness of the host-guest complex, the responsive supramolecular cell drug-loading system can be obtained after the first part and the second part are fully mixed. The preparation method is simple and rapid in preparation process, mild in condition, universal and bio-orthogonal, does not need covalent bond modification on the cell surface, and has no influence on the physiological function of the modified cell.
Recently, the trend of obesity is becoming increasingly prevalent, and the underlying pathogenesis of obesity is complex and needs to be researched further. In this study, we report a decreased expression of let-7a-5p in the white adipose tissue (WAT) of animals with obesity. Using the RNA oligo, let-7a-5p over-expression or suppression-expression is achieved, impacting the proliferation and differentiation of preadipocytes in vitro. Srebf2 mechanistically interacts with the metabolic effect of let-7a-5p and participates in lipid accumulation by regulating Srebf2 downstream signaling. Moreover, let-7a-5p binds to Thbs1 to interact with the PI3K-AKT-mTOR pathway, down-regulating the phosphorylation levels of AKT, mTOR, and S6K1 to decrease lipid accumulation. In conclusion, our study highlights the physiological significance of let-7a-5p in lipid accumulation and suggests that the let-7a-5p/Srebf2 and let-7a-5p/Thbs1/PI3K-AKT-mTOR axes may represent potential mechanisms for controlling lipid accumulation in obesity.
Participants received Mircera by subcutaneous injection once every month during the dose titration (7 months) and evaluation period (2 months). The starting dose was based on the weekly dose of darbepoetin alfa administered prior to the switch to Mircera, and was either 120, 200 or 360 µg Mircera per month. The dose was then adjusted to maintain Hemoglobin levels within the defined target range and also according to the need for red blood cell transfusions (due to worsening anemia), or for toxicity related to Mircera.
PURPOSE:The titled composition, prepared by incorporating an allantoin with an antiplasminic agent, amino acid type or nucleic acid type compound as a flavoring agent and further sodium chloride and/or potassium chloride, and having improved preventing effect on the periodontosis and improved feeling of use and high preserving power. CONSTITUTION:A composition for the oral cavity prepared by incorporating a composition containing (A) an allantoin and/or an antiplasminic agent, e.g. tranexamic acid or epsilon-aminocaproic acid, as an active constituent and (B) an amino acid type compound, e.g. l-glutamic acid or l-aspartic acid, as a flavoring agent for suppressing the bitterness or astringency of the component (A) and/or a nucleic acid type compound, e.g. inosinic acid or guanylic acid, as a flavoring agent for suppressing the bitterness or astringency of the component (A) with (C) sodium chloride and/or potassium chloride. The amounts of the respective components based on the total composition are preferably within the following ranges: 0.03-3wt% component (A), 0.001-0.3wt% component (B) and 2-20wt% component (C).
The invention discloses a preparation process of a paclitaxel albumin compound. The method comprises the following steps: (1) preparing an HSA stock solution; (2) preparing a paclitaxel stock solution; (3) preparing the paclitaxel albumin complex. The invention achieves the following excellent effects: 1. the high performance liquid chromatography shows that the binding rate of the paclitaxel is highest under the condition of pH 3.0. 2. Dynamic light scattering showed that the mean particle size was the largest at a 9:1 binding ratio of paclitaxel to HSA at pH 3.0. At pH3.0, more paclitaxel can be bound to HSA, and the larger the amount of paclitaxel bound, the larger the particle size. The Zeta potential indicates that the paclitaxel albumin complex is more stable at pH 3.0.
Low back pain has been the subject of extensive research in the past 10 years. Some of the efforts have focused on the effectiveness of diagnostic testing in determining the etiology of low back pain. One component of low back pain clinically can be sacroiliac joint (SIJ) dysfunction. The prevalence of sacroiliac pain in the low back pain population is reported to be approximately 10 to 30%. The diagnosis of sacroiliac pain has been an area of controversy in the literature with poor inter-tester and intra-rater reliability described for motion testing. More recently, a cluster of provocation tests has been described as predictive of the diagnosis of sacroiliac dysfunction. Laslett et al suggested that SI pain provocation tests used in examination should include a cluster of six tests. When three or more out of six tests or any two of four selected tests are positive, that showed the best predictive power in diagnosing SIJ pain. The "gold standard" for diagnosing SIJ pain in this study was pain relief with intra-articular local anesthetic block injection. When all six provocation tests do not provoke the patient's typical pain, the SIJ can be ruled out as a source of current low back pain.

Pelvic girdle pain including SIJ dysfunction has been investigated in post partum populations. The Active Straight Leg Raise (ASLR) has been shown to be reliable in post partum pelvic pain. This test is thought to help assess hypermobility in the SIJ. This test has a positive likelihood ratio (+LR)= 14.5 and a negative likelihood ratio (-LR)= .14 which indicates that this is a good test to rule in or rule out pelvic girdle pain in pregnancy. This test is thought to help assess dysfunction of the SIJ. The Gillet test has recently been reported to indicate abnormal biomechanics on the stance side by Hungerford et al. Increased hamstring activation on the stance leg has been identified as indicative of abnormal SI motion. These two tests (ASLR and Gillet) are thought to be reflective of SIJ instability or abnormal movement in, respectively, pregnancy or low back patients.
Our understanding of risk factors for the development of chronic lymphocytic leukemia (CLL) is still incomplete and includes genetic and environmental factors. CLL is one of the most familial of all cancers, yet common high-penetrance risk alleles have not been identified. Genome-wide association studies have identified many common variants with low relative risks, whereas exome-wide rare variant analysis has implicated ATM in CLL causation. Environmental factors have also been challenging to identify given the limited understanding of the relevant time period of exposure relative to diagnosis, and the inability to quantify past exposures. Agent Orange and glyphosate herbicides have perhaps the most data to support their role. CLL is preceded by a precursor condition called monoclonal B-cell lymphocytosis (MBL), which could therefore be considered a risk factor, but which itself is likely caused by the same risk factors that ultimately give rise to CLL. Although virtually all people with CLL have a preceding MBL phase, most people with MBL will not develop CLL.
Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy, with a maximal delay from end of chemotherapy of 2 months. Delay between FDG and 18F-K5-RGD PET scans will not exceed 2 weeks.
The invention discloses an achyranthes prescription granule and a preparation method as well as a quality control method thereof. The prescription granule uses achyranthes decoction pieces as raw materials to prepare the achyranthes prescription granule through the technique procedures, such as twice water extraction, vacuum concentration, sponging drying, etc. 1g of the achyranthes prescription granule is equal to 3-5g of crude drug. The quality of the achyranthes decoction pieces and the achyranthes prescription granule are identified by using infrared fingerprint spectra. The achyranthes prescription granule of the invention has complete and advanced production technique, specific and controllable quality control standard, scientific, advanced, rapid and operable detecting method related to the quality standard. A great number of experiments prove that the prepared soup of the achyranthes prescription granule and the mixed simmered liquid of the classical prescription decoction pieces containing achyranthes have equal components, thus realizing the technique of full ingredient prescription granule and proving the reasonability of the technique of the invention; and in the invention, infrared spectroscopy technology is used for the quality control of the traditional Chinese medicines, rapidly solving a primary problem in macroscopic quality control of the traditional Chinese medicines-the identification of the truth of traditional Chinese medicines.
In a method of accelerating the dissolution of hard-soluble lyophilized medicaments based on proteins, a magnetic body 13 is introduced into an end container 6 under sterile conditions prior to the lyophilization of the batch. The end container 6 is brought into the region of a magnetic rotary field after addition of a solvent to the lyophilized batch, whereupon the magnetic body 13 is set in motion. An arrangement for carrying out the method includes a heatable block 2 of antimagnetic material with one or more accommodation openings 3, 3', 3'' etc. for the end containers. A rotating magnetic stirrer 8 is installed below the accommodation openings. <IMAGE>
Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.
Based on PK data from 1st Interim Analysis BID administration of oral EBP11. The selected BID dose to be administered will be either 1.5, 2.0 or 2.5 mg.
If the patient is in group 1, she will get standard education for weight loss, which will be provided by her Gynecologic Oncologist. This will take about 15 minutes.
A theragnostic system includes a surgical station and a storage and processing device that contains data in a suitable storage in which patient data and treatment data, e.g. in form of electrical and optical features, are combined. The electrical features are derived from electrical parameters of the voltage and the current with which an instrument is supplied. The optical features are derived from light of the spark that is produced upon influencing the tissue. By combining electrical and optical features in a data collection, that even contains additional features, such as tissue features and patient characteristics, it can be determined whether the instrument influences benign or malign tissue. The prediction accuracy can be increased by machine learning by adding histological data to the data sets. These data can be collected in a cloud computing system that is connected with many surgical stations.
PCT No. PCT/EP91/02494 Sec. 371 Date Jun. 22, 1993 Sec. 102(e) Date Nov. 1, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11278 PCT Pub. Date Jul. 9, 1992.Novel compounds of the general formula I    <IMAGE>  (I)  and the pharmacologically tolerable addition salts thereof with acids are described, in which either Ia) R11 represents a hydrogen atom in the  beta -configuration and each of R12 and R13 represents a hydrogen atom, or Ib) R11 represents a hydrogen atom in the  beta -configuration and R12 and R13 together represent a second bond, or Ic) R11 and R12 together represent a second bond and R13 represents a hydrogen atom, or Id) R11 represents a hydrogen atom in the  alpha -configuration and R12 and R13 together represent a second bond, and in Ia), Ib), Ic) or Id) X represents an oxygen atom, the hydroxyimino grouping >N DIFFERENCE OH or two hydrogen atoms, R1 represents a hydrogen atom or a methyl group, R2 represents a hydroxy group, a C1-C10-alkoxy group or a C1-C10-acyloxy group, and R3 and R4 have the meanings customary for competitive progesterone antagonists specified in the description. The invention relates also to processes for the preparation of the novel compounds, to pharmaceutical compositions containing those compounds, to their use for the manufacture of medicaments, and to the novel intermediates required for the process. The novel compounds have a strong affinity for the gestagen receptor and exhibit pronounced antigestagenic and also antiglucocorticoid, antimineralocorticoid and antiandrogenic properties.